AOD-9604 fat loss: the trials nobody ever published

AOD-9604 went further into human testing than most peptides you will find at a compounding clinic today. A real pharmaceutical company, serious funding, a programme that ran to a properly powered trial. And it failed to beat placebo when the stakes were highest. That sequence tells you something specific about how this peptide works, and it is the most important thing to understand before you add it to a fat-loss protocol.

AOD-9604 is a synthetic fragment of human growth hormone: the last 16 amino acids of the chain (positions 176 to 191) with a tyrosine tacked on the front. Developed by Metabolic Pharmaceuticals, a Monash University spin-out in Melbourne, it had one design goal: capture the fat-releasing effect of growth hormone without the insulin resistance that full-length GH produces at fat-loss doses.

The mechanism is well established in animal models. AOD-9604 activates beta-3 adrenergic receptors on fat cells, triggering the breakdown of stored fat into free fatty acids. It does not raise IGF-1. It does not suppress insulin. In obese Zucker rats, 500 micrograms per kilogram per day for 19 days cut weight gain by more than 50 percent compared to untreated controls without impairing glucose metabolism, according to Ng et al. in Hormone Research (2000). That is exactly the profile you want in an obesity drug. And then came the human data.

What did the Phase IIa trial show, and why did it raise hopes?

The Phase IIa trial tested several oral dose levels against placebo over 12 weeks. The result that generated press coverage came from the lowest active dose, 1 mg per day, which was reported to separate from placebo on fat loss. The specific kilogram figures quoted everywhere online come from company announcements rather than a published trial report, so treat the size of that separation as unverified.

Two features of the Phase IIa account were already concerning at the time. First, the dose-response ran backwards: the higher dose groups performed worse than the 1 mg group. A compound where more is less is unusual for a drug candidate and makes it very hard to optimise. Second, even on the sponsor's own telling, the benefit over placebo was modest. Metabolic Pharmaceuticals pressed on to the pivotal trial anyway.

Why did the pivotal 24-week trial fail despite the earlier signal?

The Phase IIb "OPTIONS" trial enrolled 536 subjects across multiple countries, testing doses of 0.25, 0.5, and 1 mg per day orally for 24 weeks. Double-blind, randomized, multicenter, powered to detect a clinically meaningful weight difference. The result was unambiguous: no statistically significant difference in weight loss versus placebo at any dose tested.

"The Phase 2B trial results for AOD9604 do not support the commercial viability of the drug as a treatment for obesity. The compound appeared safe and well-tolerated, but the efficacy signal from the earlier trial did not replicate at scale."

Valentino, Lin, and Waldman, Clinical Pharmacology and Therapeutics, 2010

Metabolic Pharmaceuticals discontinued the obesity program in 2007. Across all six trials, no serious adverse events were recorded. The compound was safe. It simply did not produce sustained, clinically meaningful fat loss in a properly powered human study. The company later pivoted to licensing AOD-9604 as a cosmetic ingredient (Phosphagenics acquired it for an anti-cellulite cream, BodyShaper) and explored an oral formulation for osteoarthritis, both of which also stalled without regulatory approval. Human therapeutic development ceased entirely.

Why do the first few weeks seem to work if the long-duration trial failed?

This is the question most coverage of AOD-9604 does not answer, and it matters practically for anyone considering it today. The Phase IIa trial ran 12 weeks and found a signal. The Phase IIb trial ran 24 weeks and found nothing. The signal that appeared at 12 weeks had disappeared by 24 weeks. That pattern points to a fat-releasing effect that is real but self-limiting over time.

Beta-3 adrenergic receptor downregulation is a well-documented phenomenon. Chronic stimulation of beta adrenergic receptors reduces receptor density and coupling efficiency over time. If AOD-9604 produces a burst of fat release in the first 4 to 8 weeks that gradually attenuates as receptors desensitize, a 12-week trial would capture the burst while a 24-week trial would capture the return to baseline. This has not been directly tested in the AOD-9604 program, but it is mechanistically consistent with what the trial data shows.

The practical implication for anyone who uses it: short cycles with breaks may produce better results than continuous dosing. Continuous daily administration for 24 weeks is probably not the optimal protocol, even though that is exactly what the pivotal trial tested. For how receptor desensitization shapes cycling decisions across peptide classes, the peptide cycling protocol guide covers this mechanism in detail.

How does AOD-9604 compare to semaglutide for fat loss?

Some wellness clinics market AOD-9604 as a "non-GLP-1 fat-loss alternative" following compounded semaglutide restrictions in 2025 and 2026. This framing is misleading, and the evidence gap between these two approaches is very large.

The comparison is not close on efficacy. If your goal is meaningful sustained fat loss, the clinical evidence overwhelmingly favors GLP-1 drugs. AOD-9604 occupies a different niche: potentially useful in short cycles for people who cannot or will not use GLP-1 drugs, but without the regulatory standing, mechanism of action, or efficacy profile to function as a replacement. For a detailed look at which genetics predict GLP-1 non-response, the semaglutide non-responder genetics guide covers the relevant variants.

Why a flat average can hide two very different groups of people

Here is what none of the trials ever answered: who were the responders, and did anything inherited separate them from the non-responders? The results were reported as averages across everyone enrolled. If one subgroup lost meaningful fat while another lost nothing, the average would look flat either way. That may be part of what happened in the pivotal trial.

AOD-9604 works by opening the beta-3 receptor, the release valve on a fat cell. The gene that builds that receptor is ADRB3, and one common version of it, rs4994 or Trp64Arg, passes the signal on less efficiently once the valve is triggered. A 2020 meta-analysis in Adipocyte covering 16 studies and 12,497 subjects found that Trp64Arg carriers have 23 to 39 percent higher odds of overweight and obesity, with the strongest signal in East Asian populations. If your ADRB3 receptor does not couple efficiently, AOD-9604 is activating a pathway that is already impaired in your biology. The early trial data also suggests a non-linear response: the 1 mg/day dose outperformed all higher doses. Receptor-level impairment may explain both the non-linearity and the between-subject variability.

There is a second layer. LEPR builds the docking point for leptin, the hormone that tells your brain you have eaten enough, and the versions that dull that signal are common in people who struggle most with fat loss. AOD-9604 does not work through the leptin pathway at all, so LEPR-driven weight resistance is not addressed and not overcome by the peptide. For a broader framework on how beta-adrenergic, leptin, and GLP-1 pathways interact in fat-loss response, the peptides for weight loss guide covers the multi-pathway picture. For the full decision tree across peptide categories, the DNA-first peptide selection framework maps out how to use those results.

Is AOD-9604 legal to use in the United States right now?

In the United States, AOD-9604 cannot currently be legally compounded. The FDA's Pharmacy Compounding Advisory Committee voted against including it on the 503A Bulk Drug Substances List at its December 4, 2024 meeting, citing an inadequate chemical description of the substance and insufficient evidence that it works. The compound was removed from Category 2 of the interim 503A bulks list on September 27, 2024 (the nominator withdrew), reverting to default prohibition status. There is no 503B outsourcing facility pathway either. Products sold online operate entirely outside FDA oversight.

One regulatory fact that is consistently misrepresented: AOD-9604 holds an FDA GRAS notice (GRN 000546, 2014), meaning it is Generally Recognized As Safe for use as a food ingredient. Some vendors cite this as regulatory approval or a safety endorsement. It is neither. GRAS is a food designation with a separate and much lower evidence bar than drug approval. It does not legalize injectable, therapeutic, or human drug use.

In Australia, where the compound was developed, AOD-9604 is Schedule 4 (prescription-only) under the TGA Poisons Standard, effective June 2015, partly driven by ASADA scrutiny following the 2012 to 2013 Essendon AFL supplements scandal. With no listing on the Australian Register of Therapeutic Goods (ARTG), no prescribing or dispensing pathway exists for any practitioner. The drug was never approved. Older articles that cite TGA "listed complementary medicine" status as a form of approval are wrong: TGA-listed products are not evaluated for efficacy before listing.

For competitive athletes anywhere in the world: WADA classifies AOD-9604 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth hormone fragment, non-specified status. The prohibition has been in place since at least 2011 and is carried through the 2026 Prohibited List. A positive test carries a four-year ban with no therapeutic use exemption available for any indication.

Who is actually a reasonable candidate for AOD-9604 today?

Given the full evidence profile, there is a narrow honest case for AOD-9604 in specific circumstances. You need: realistic expectations of modest early fat mobilization (not sustained weight loss); willingness to operate in the legal grey zone outside the U.S.; ADRB3 genetics that do not already impair the target pathway; and a goal that does not require the kind of body weight reduction that only GLP-1 drugs have demonstrated at scale.

The strongest theoretical case is for short cycles of 4 to 8 weeks in people with intact ADRB3 signaling who are adding AOD-9604 as an adjunct to an existing fat-loss protocol, not as a primary intervention. The weakest case is for anyone expecting sustained results comparable to the Phase IIa outcome, anyone carrying ADRB3 Trp64Arg, anyone competing in a tested sport, or anyone in the United States trying to source it through a licensed compounding pharmacy.

If sustained fat loss is the primary goal, the weight of evidence points to GLP-1 drugs for people who can access and tolerate them. If those are not an option and you want to understand how AOD-9604 fits relative to other peptide-based fat-loss options, the AOD-9604 peptide profile covers mechanism comparisons in detail. The honest read from the six-trial record is that AOD-9604 produced a real but modest signal at 12 weeks that vanished by 24 weeks. That is the entire evidentiary foundation for everything being sold today.